Cord Blood Amer Inc. (WKN: A0EAGC / CBAI) / OTCBB

... danke für den Hinweis!

Da Obama ja nun seine Garantie für die Stammzellenforschung gegeben hat und der US-Senat einige Streichungen vorgenommen hat, würde mich interessieren, um welche Höhe es bei den Forschungsgeldern geht und in welches Ressort das fällt. Eventuell National Institutes of Health grants? Jemand eine Info dazu?

Gruß, TexX  

http://ih.advfn.com/...&cb=1234108482&article=36117095&symbol=NB^CBAI

In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors

SANTA MONICA, Calif., Feb. 5 /PRNewswire-FirstCall/

Cord Blood America, Inc. (OTC:CBAI) (BULLETIN BOARD: CBAI) , the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, explained that the Company is very close to becoming cash flow positive.

The complete interview is available at http://www.stoxrox.com/cbai-feb-b.mp3 . "2009 is a tipping point year for Cord Blood America. We will continue our organic growth strategy, adding new health insurance partners and possible new acquisitions, while continuing to reduce debt," Mr. Schissler said.

Cord Blood America's CEO said he was encouraged that more Federal spending on stem cell research under President Obama could lead to more stem cell therapies which, in turn, will lead to more families storing stem cells. "The stem cell agenda is front and center with the new Administration," Mr. Schissler said.

Cord Blood America's CEO also referenced the cover story of the new Time magazine, which cited breakthroughs using stem cells to treat Parkinson's, heart disease and diabetes. "Investors should understand, in storing umbilical cord blood stem cells, we have a significant biological annuity with low bad debt ratio, strong gross profits, and a low cost structure in place that will allow us to take full advantage of the expected increase in the storage of stem cells," the Company's founder said.

About Cord Blood America

Cord Blood America (OTC:CBAI) (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC:CBAI) (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT: Paul Knopick E & E Communications 949/707-5365

DATASOURCE: Cord Blood America, Inc.

CONTACT: Paul Knopick, E & E Communications, +1-949-707-5365,

, for Cord Blood America, Inc.

Web Site: http://www.cordblood-america.com/

http://www.whitehouse.gov/agenda/health_care/

HEALTH CARE

On health care reform, the American people are too often offered two extremes -- government-run health care with higher taxes or letting the insurance companies operate without rules. President Obama and Vice President Biden believe both of these extremes are wrong, and that’s why they’ve proposed a plan that strengthens employer coverage, makes insurance companies accountable and ensures patient choice of doctor and care without government interference.

The Obama-Biden plan provides affordable, accessible health care for all Americans, builds on the existing health care system, and uses existing providers, doctors, and plans. Under the Obama-Biden plan, patients will be able to make health care decisions with their doctors, instead of being blocked by insurance company bureaucrats.

Under the plan, if you like your current health insurance, nothing changes, except your costs will go down by as much as $2,500 per year. If you don’t have health insurance, you will have a choice of new, affordable health insurance options.
Make Health Insurance Work for People and Businesses -- Not Just Insurance and Drug Companies.

   * Require insurance companies to cover pre-existing conditions so all Americans regardless of their health status or history can get comprehensive benefits at fair and stable premiums.
   * Create a new Small Business Health Tax Credit to help small businesses provide affordable health insurance to their employees.
   * Lower costs for businesses by covering a portion of the catastrophic health costs they pay in return for lower premiums for employees.
   * Prevent insurers from overcharging doctors for their malpractice insurance and invest in proven strategies to reduce preventable medical errors.
   * Make employer contributions more fair by requiring large employers that do not offer coverage or make a meaningful contribution to the cost of quality health coverage for their employees to contribute a percentage of payroll toward the costs of their employees' health care.
   * Establish a National Health Insurance Exchange with a range of private insurance options as well as a new public plan based on benefits available to members of Congress that will allow individuals and small businesses to buy affordable health coverage.
   * Ensure everyone who needs it will receive a tax credit for their premiums.

Reduce Costs and Save a Typical American Family up to $2,500 as reforms phase in:

   * Lower drug costs by allowing the importation of safe medicines from other developed countries, increasing the use of generic drugs in public programs, and taking on drug companies that block cheaper generic medicines from the market.
   * Require hospitals to collect and report health care cost and quality data.
   * Reduce the costs of catastrophic illnesses for employers and their employees.
   * Reform the insurance market to increase competition by taking on anticompetitive activity that drives up prices without improving quality of care.

The Obama-Biden plan will promote public health. It will require coverage of preventive services, including cancer screenings, and increase state and local preparedness for terrorist attacks and natural disasters.

A Commitment to Fiscal Responsibility: Barack Obama will pay for his $50 - $65 billion health care reform effort by rolling back the Bush tax cuts for Americans earning more than $250,000 per year and retaining the estate tax at its 2009 level.

 

http://www.marketwire.com/press-release/...od-America-Inc-947152.html

Feb 09, 2009 09:35 ET
Cord Blood America Now Part of New ETF Innovators Stem Cell Index

SANTA MONICA, CA--(Marketwire - February 9, 2009) - Cord Blood America, Inc. (OTCBB: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that the Company is now listed on the ETF Innovators Emerging Stem Cell Index of U.S.-listed stocks. For more information, see the social media news room at http://www.intelligendo.com.

ETF Innovators, known for creating new global equity indexes with a focus in the healthcare industry, will track the total market value and stock price changes as an indicator of investor and trader sentiment toward the stem cell and regenerative medicine space.

"We are pleased by this recognition. Two thousand and nine has been, so far, both very interesting and positive for stem cell companies, and we're pleased to see this impressive index following our sector," said Matthew Schissler, Founder and CEO of Cord Blood America.

About Cord Blood America

Cord Blood America (OTCBB: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTCBB: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

09.02.2009 09:07

Gekürztes US-Konjunkturpaket dürfte vor Genehmigung stehen

Washington (BoerseGo.de) - Im US-Senat erzielten am Wochenende Demokraten und Republikaner eine Einigung zum geplanten Konjunkturprogramm der Regierung. Das ausgehandelte Paket umfasst ein Volumen von rund 780 Milliarden Dollar. Damit wurde wegen dem Widerstand der Republikaner der von der Regierung ursprünglich vorgelegte Entwurf um über 150 Milliarden Dollar gekürzt. Das Weiße Haus hat den Kompromiss begrüßt. Zuvor warnte Präsident Barack Obama vor katastrophalen Folgen für die Wirtschaft, falls das Paket zu keiner Verabschiedung gelangt. Der Senat will kommenden Dienstag über den Entwurf abstimmen.


Gruß TexX  

Das Time-Magazin mit dem Stem Cell Artikel "How the Coming Revolution in Stem Cells Could Save Your Life" sollte am 9. Februar, also heute in den USA erscheinen.

Das News-Magazin ist laut Wikipedia mit einer Gesamtauflage von rund 5,2 Mio. Exemplaren Marktfüher in den USA.

Gruß, TexX  

Filing vom 10.02.2009

http://pinksheets.com/edgar/GetFilingHtml?FilingID=6392580

sowie "OTC Select Announces Morning Daily Stock Watch"

http://www.worldstockwire.com/viewpressrelease/prID/739/

 

HINWEIS:
...diese Artikel beziehen sich generell auf die Stammzellenforschung! - sie sind nicht! allein bezogen auf CBAI !!!

**************************************************

http://edition.cnn.com/2009/HEALTH/02/11/...ndex.html?eref=rss_latest


February 11, 2009 -- Updated 2151 GMT
Man appears free of HIV after stem cell transplant

By Jacquelyne Froeber
Health

A 42-year-old HIV patient with leukemia appears to have no detectable HIV in his blood and no symptoms after a stem cell transplant from a donor carrying a gene mutation that confers natural resistance to the virus that causes AIDS, according to a report published Wednesday in the New England Journal of Medicine.
The patient underwent a stem cell transplant and since, has not tested positive for HIV in his blood.

"The patient is fine," said Dr. Gero Hutter of Charite Universitatsmedizin Berlin in Germany. "Today, two years after his transplantation, he is still without any signs of HIV disease and without antiretroviral medication."

The case was first reported in November, and the new report is the first official publication of the case in a medical journal. Hutter and a team of medical professionals performed the stem cell transplant on the patient, an American living in Germany, to treat the man's leukemia, not the HIV itself.

However, the team deliberately chose a compatible donor who has a naturally occurring gene mutation that confers resistance to HIV. The mutation cripples a receptor known as CCR5, which is normally found on the surface of T cells, the type of immune system cells attacked by HIV.

The mutation is known as CCR5 delta32 and is found in 1 percent to 3 percent of white populations of European descent.

HIV uses the CCR5 as a co-receptor (in addition to CD4 receptors) to latch on to and ultimately destroy immune system cells. Since the virus can't gain a foothold on cells that lack CCR5, people who have the mutation have natural protection. (There are other, less common HIV strains that use different co-receptors.)

People who inherit one copy of CCR5 delta32 take longer to get sick or develop AIDS if infected with HIV. People with two copies (one from each parent) may not become infected at all. The stem cell donor had two copies.

While promising, the treatment is unlikely to help the vast majority of people infected with HIV, said Dr. Jay Levy, a professor at the University of California San Francisco, who wrote an editorial accompanying the study. A stem cell transplant is too extreme and too dangerous to be used as a routine treatment, he said.

"About a third of the people die [during such transplants], so it's just too much of a risk," Levy said. To perform a stem cell transplant, doctors intentionally destroy a patient's immune system, leaving the patient vulnerable to infection, and then reintroduce a donor's stem cells (which are from either bone marrow or blood) in an effort to establish a new, healthy immune system.

Levy also said it's unlikely that the transplant truly cured the patient in this study. HIV can infect many other types of cells and may be hiding out in the patient's body to resurface at a later time, he said.

"This type of virus can infect macrophages (another type of white blood cell that expresses CCR5) and other cells, like the brain cells, and it could live a lifetime. But if it can't spread, you never see it-- but it's there and it could do some damage," he said. "It's not the kind of approach that you could say, 'I've cured you.' I've eliminated the virus from your body." Health.com: 10 questions to ask a new partner before having sex

Before undergoing the transplant, the patient was also found to be infected with low levels of a type of HIV known as X4, which does not use the CCR5 receptor to infect cells. So it would seem that this virus would still be able to grow and damage immune cells in his body. However, following the transplant, signs of leukemia and HIV were absent.

"There is no really conclusive explanation why we didn't observe any rebound of HIV," Hutter said. "This finding is very surprising."

Hutter noted that one year ago, the patient had a relapse of leukemia and a second transplant from the same donor. The patient experienced complications from the procedure, including temporary liver problems and kidney failure, but they were not unusual and may occur in HIV-negative patients, he said.

Researchers including Hutter agree that the technique should not be used to treat HIV alone. "Some people may say, 'I want to do it,'" said Levy. A more logical -- and potentially safer -- approach would be to develop some type of CCR5-disabling gene therapy or treatment that could be directly injected into the body, said Levy.

Less invasive options to alter CCR5 could be on the horizon within the next five years, said Levy. "It's definitely the wave of the future," he said. "As we continue to follow this one patient, we will learn a lot."

One drug that's currently on the market that blocks CCR5 is called maraviroc (Selzentry). It was first approved in 2007 and is used in combination with other antiretroviral drugs. Health.com: Who's most at risk for STDs?

In 2007, an estimated 2 million people died from AIDS, and 2.7 million people contracted HIV. More than 15 million women are infected worldwide. HIV/AIDS can be transmitted through sexual intercourse, sharing needles, pregnancy, breast-feeding, and/or blood transfusions with an infected person. Health.com:What should I do if the condom breaks?

"For HIV patients, this report is an important flicker of hope that antiretroviral therapy like HAART [highly active antiretroviral therapy] is not the endpoint of medical research," Hutter said.


Copyright Health Magazine 2009

**************************************************

http://content.nejm.org/cgi/content/abstract/360/7/692

Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Gero Hütter, M.D., Daniel Nowak, M.D., Maximilian Mossner, B.S., Susanne Ganepola, M.D., Arne Müßig, M.D., Kristina Allers, Ph.D., Thomas Schneider, M.D., Ph.D., Jörg Hofmann, Ph.D., Claudia Kücherer, M.D., Olga Blau, M.D., Igor W. Blau, M.D., Wolf K. Hofmann, M.D., and Eckhard Thiel, M.D.


Infection with the human immunodeficiency virus type 1 (HIV-1) requires the presence of a CD4 receptor and a chemokine receptor, principally chemokine receptor 5 (CCR5). Homozygosity for a 32-bp deletion in the CCR5 allele provides resistance against HIV-1 acquisition. We transplanted stem cells from a donor who was homozygous for CCR5 delta32 in a patient with acute myeloid leukemia and HIV-1 infection. The patient remained without viral rebound 20 months after transplantation and discontinuation of antiretroviral therapy. This outcome demonstrates the critical role CCR5 plays in maintaining HIV-1 infection.


Source Information

From the Department of Hematology, Oncology, and Transfusion Medicine (G.H., D.N., M.M., S.G., A.M., O.B., I.W.B., W.K.H., E.T.) and the Department of Gastroenterology, Infectious Diseases, and Rheumatology (K.A., T.S.), Campus Benjamin Franklin; and the Institute of Medical Virology, Campus Mitte (J.H.) — all at Charité Universitätsmedizin Berlin; and the Robert Koch Institute (C.K.) — all in Berlin.

Drs. Hofmann and Thiel contributed equally to this article.

Address reprint requests to Dr. Hütter at Medical Department III Hematology, Oncology, and Transfusion Medicine, Charité Campus Benjamin Franklin, Hindenburgdamm 30 D-12203 Berlin, Germany, or at gero.huetter@charite.de.

http://finance.yahoo.com/news/...ood-Announces-1-prnews-14333913.html

Cord Blood Announces $1 Million Reduction in Long Term Debt

   * Thursday February 12, 2009, 6:00 am EST

SANTA MONICA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that between January 1, 2009, and today, it has reduced its long term debt by approximately $1 million.

The Company previously said in press releases and CEO interviews that a major focus is to reduce debt and strengthen the Cord Blood America balance sheet. The mentioned debt was either converted into equity of reduced by principal cash payment. Cord Blood America said the effort to further reduce debt will continue throughout 2009.

CEO Matthew Schissler commented: "It's a start. De-levering our balance sheet coupled with strategic growth and acquisitions are the primary goals for 2009. I'm certain shareholders would agree that removing debts will help put the company in a strong position for long term growth in the stem cell industry."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

MoneyTV-Umbilical Cord Blood Stem Cell Storage
13. Februar 2009
http://www.youtube.com/watch?v=yQC_32u6hn4

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6412518

...As of February 12, 2009 a total of 942,884,111 shares of the Company's currently authorized 950,000,000 shares of Common Stock are outstanding.

http://www.reuters.com/article/domesticNews/idUSTRE51E12220090215

Obama to lift ban on stem cell research soon
Sun Feb 15, 2009 10:01am EST

WASHINGTON (Reuters) - U.S. President Barack Obama will soon issue an executive order lifting an eight-year ban embryonic stem cell research imposed by his predecessor, President George W. Bush, a senior adviser said on Sunday.

"We're going to be doing something on that soon, I think. The president is considering that right now," Obama adviser David Axelrod said on "Fox News Sunday."

In 2001, Bush limited federal funding for stem cell research only to human embryonic stem cell lines that already existed. It was a gesture to his conservative Christian supporters who regard embryonic stem cell research as destroying potential life, because the cells must be extracted from human embryos.

Embryonic stem cells are the most basic human cells which can develop into any type of cell in the body.

Scientists believe the research could eventually produce cures for a variety of diseases, including Parkinson's disease, diabetes, heart disease and spinal cord injuries.

Obama vowed to reverse Bush's ban during his presidential campaign and in his inaugural address last month promised to return science to its proper place in the United States.

The U.S. Food and Drug Administration last month cleared the way for the first trial to see if human embryonic stem cells could treat people safely.

The trial will try to use stem cells from already existing lines to regrow nerve tissue in patients with crushed spinal cords.

Stem cells are the body's master cells, giving rise to all the tissues, organs and blood. Embryonic stem cells are considered the most powerful kinds of stem cells, as they have the potential to give rise to any type of tissue.

(Reporting by Alan Elsner; Editing by Eric Beech)

© Thomson Reuters 2009 All rights reserved

http://newmexicoindependent.com/19228/...research-passes-state-senate

http://politicalticker.blogs.cnn.com/2009/02/19/...urn-stem-cell-ban/

February 19, 2009
Republicans urge Obama to overturn stem cell ban

...The Republicans said that stem cell research holds "great promise" for Americans suffering from afflictions like Parkinson's disease, spinal cord injuries and diabetes.

http://ih.advfn.com/...125706&article=36346806&symbol=NB^CBAI

...The television program can also be viewed online immediately at http://www.moneytv.net/.

http://biz.yahoo.com/prnews/090220/la73335.html?.v=1

In Analyst Interview, Cord Blood Provides Details of Special Shareholder Meeting
Friday February 20, 5:00 am ET

SANTA MONICA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company ( http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, provided details of the Company's special shareholder meeting in March.

ADVERTISEMENT
The complete interview is available at: http://www.stoxrox.com/cbai-2-18-09-e.mp3

In the interview, Mr. Schissler explains why the Company is asking for an increase in authorized shares. He explains that authorized is "vastly different from outstanding" and the Company currently has no commitments or understandings for the issuance of additional outstanding shares other than those currently on file at the SEC.

"Our goal is to be ahead of the game. We want to grow the Company into a global leader in the storage of stem cells and that includes the ability to act and react quickly. We also want to benefit from what we believe will be greatly increased research in this sector. This lets us control our destiny," Mr. Schissler said. Asked why Cord Blood America is asking for such a large increase in authorized shares, the Company's founder said "this is a time-consuming, costly process and we only want to do it once in the Company's history."

...

http://www.finanznachrichten.de/...s-to-be-cash-flow-positive-008.htm

25.02.2009 11:01
Cord Blood America Restructures Debt; Projects to be Cash Flow Positive

SANTA MONICA, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced an agreement with Shelter Island Opportunity Fund to restructure its current outstanding debt.

"The restructuring is a major step forward for Cord Blood America. With the signing of the agreement, Cord Blood America projects it will become cash flow positive for the first time in its history," said Matthew Schissler, Founder and CEO. "We anticipate formally being able to announce this when we file our quarterly numbers for period ending June 30, 2009."

"We have emphasized to our shareholders that reducing debt is a major focus in 2009," Mr. Schissler said. "This agreement provides us the opportunity to follow through on our commitment." The Company recently announced that since the beginning of 2009, it has reduced long term debt by more than $1 million.

...(weiter siehe LINK)

http://www.marketwire.com/press-release/Cord-Blood-America-957764.html

Mar 05, 2009 09:45 ET
Cord Blood America Top Stock Performer in ETF Innovators Global Stem Cell and Regenerative Medicine Index

SANTA MONICA, CA--(Marketwire - March 5, 2009) - On the day that President Obama's White House Health Care Summit commenced, Cord Blood America, Inc. (OTCBB: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, reported that the Company, now listed on the ETF Innovators Emerging Stem Cell Index of U.S.-listed stocks, is the top stock price gainer year-to-date, up 279.2 percent. For more information, see Cord Blood America's Social Media News Room and Blogs at Intelligendo.com.

The analysis is available at: http://www.biomedreports.com/articles/...-of-stem-cell-index-ytd.html

... (weiter siehe LINK)

http://www.finanznachrichten.de/...-cell-funding-restrictions-008.htm

09.03.2009 15:24
Cord Blood America Sees Significant Positives in President Obama's Lifting of Stem Cell Funding Restrictions

SANTA MONICA, Calif., March 9 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it believes the executive order signed today by President Obama eliminating restrictions on Federal funding of stem cell research is a significant move forward for the entire stem cell sector.

"Scientists are confident that stem cell research will lead to fundamental improvements in the treatment of heart disease, diabetes, Parkinson's disease and other of our most difficult to treat illnesses," said Matthew Schissler, Cord Blood America Founder and CEO.

... (weiter siehe LINK)

http://www.marketwatch.com/news/story/...F404-4A60-AE9C-67AE5EE93061}

Obama ends stem-cell ban, asks for science with moral values
By Rex Nutting
Last update: 12:01 p.m. EDT March 9, 2009

WASHINGTON (MarketWatch) -- President Barack Obama lifted a ban on federal funding for stem-cell research, calling on Monday for a return to integrity in the government's scientific strategy. "It is about ensuring that scientific data is never distorted or concealed to serve a political agenda - and that we make scientific decisions based on facts, not ideology," Obama said. Stem-cell research has great promise for cures and treatments in many diseases, especially of the brain and nervous system. But most stem cells have come from human embryos. Obama said he would resist any research that leads to human cloning, calling it dangerous and "profoundly wrong.

http://www.finanznachrichten.de/...hareholder-special-meeting-008.htm

25.03.2009 10:03
Cord Blood America Announces Results of Shareholder Special Meeting

SANTA MONICA, Calif., March 25 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that its shareholders at a Special Meeting on March 23, 2009, have overwhelming approved management's proposal to increase the number of authorized (not outstanding) common shares. The vote is being certified, at which time Cord Blood America will file the results with the U.S. Securities and Exchange Commission.

About Cord Blood America

Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI), visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT: Paul Knopick E&E Communications 949/707-5365 pknopick@eandecommunications.com

http://www.finanznachrichten.de/...porting-cord-blood-storage-008.htm

27.03.2009 10:01
Cord Blood America Applauds Congressional Effort Supporting Cord Blood Storage

SANTA MONICA, Calif., March 27 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it strongly supports the Family Cord Blood Banking Act introduced in the U.S. House of Representatives.

The legislation will provide tax incentives for the medical expenses for those families choosing this potentially life-saving investment. It amends the Internal Revenue Code to add cord blood banking services as a qualified medical expense. "This would allow individuals and couples to pay for umbilical cord blood banking services through health savings accounts, flexible spending accounts, medical expenses tax deduction and health reimbursement arrangements," said Matthew Schissler, CEO and Founder, Cord Blood America.

The legislation was introduced by Representatives Wally Herger (R-CA.), Rep. Ron Kind (D-WI), Mike Thompson (D-CA), Artur Davis (D-AL), and Bill Pascrell Jr. (D-NJ). The Congressmen in a press statement said "umbilical cord blood stem cells have been used in more than 14,000 transplants around the world and to treat more than 70 diseases in adults and children. The legislation could make this storage an option for more families facing potentially life-threatening diseases, increase the supply of cord blood stem cells and lower the costs for families in the future."

...(weiter siehe LINK)

http://www.finanznachrichten.de/...ny-commitment-to-expansion-008.htm

09.04.2009 11:01
Cord Blood America Announces First Storage Sale in Germany; Commitment to Expansion

SANTA MONICA, Calif., April 9 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said that its international partner, a.bourkas Co., United, Greece, has established a sales operation, and completed their first sale in Germany.

"Europe is starting to look more closely at the collection and storage of umbilical cord blood, which contains stem cells that could be useful for treatment of diabetes, heart disease and other illnesses that are currently impossible to cure," said Matthew Schissler, Cord Blood America Founder and CEO.

"We have been in a partnership in Greece since 2006 and we are very encouraged by their efforts to bring this life saving process to other nations on the European continent," Mr. Schissler said. "We see this as a new, potentially very profitable frontier and we are pleased to be among the leaders in this effort. We are committed to expansion and growth."

...(weiter siehe LINK)